Banner - Home

Free Welchol Samples
Register to receive in-office support materials, patient savings information, and free samples of Welchol.
Request Samples

Add Welchol.
Help Appropriate Patients Meet the Challenge.

Welchol is the only FDA-approved therapy for lowering LDL-C and A1C with one active ingredient in adults with primary hyperlipidemia and type 2 diabetes.1

What are you adding to your statin to help meet the challenge? Welchol is the only statin add-on that can reduce elevated LDL-C and improve glycemic control—that's the Welchol difference.

Learn More

The photos depict models, not actual patients or healthcare professionals.

Efficacy and Dosing

Welchol Efficacy

Welchol may provide benefits for adult patients with primary hyperlipidemia, type 2 diabetes, or both.


Welchol Dosing

Offer your patients 2 different dosing formulations. Choose from Welchol tablets or Welchol for oral suspension.


Free Welchol Samples

Welchol Resources for You and Your Patients

Based on a $0 co-pay for a 90-day supply or a $10 co-pay for a 30-day supply. Restrictions apply based on eligibility. See Terms & Conditions below.


Important Safery Information


Welchol is indicated as an adjunct to diet and exercise to:

  • reduce elevated low-density lipoprotein cholesterol (LDL-C) in patients with primary hyperlipidemia (Fredrickson Type IIa) as monotherapy or in combination with an hydroxymethyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor (statin)
  • reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia, as monotherapy or in combination with a statin after failing an adequate trial of diet therapy
  • improve glycemic control in adults with type 2 diabetes mellitus
Important Limitations of Use
  • Welchol should not be used for the treatment of type 1 diabetes or for the treatment of diabetic ketoacidosis
  • Welchol has not been studied in type 2 diabetes in combination with a dipeptidyl peptidase-4 inhibitor
  • Welchol has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias
  • Welchol has not been studied in children younger than 10 years of age or in premenarchal girls



Welchol is contraindicated in:

  • individuals with a history of bowel obstruction
  • those with serum triglyceride (TG) concentrations of >500 mg/dL, or
  • those with a history of hypertriglyceridemia-induced pancreatitis.
Warnings and Precautions

The effect of Welchol on cardiovascular morbidity and mortality has not been determined.

Welchol can increase serum TG concentrations particularly when used in combination with pioglitazone, sulfonylureas, or insulin. Caution should be exercised when treating patients with TG levels >300 mg/dL.

Welchol may decrease the absorption of fat-soluble vitamins A, D, E, and K. Patients on vitamin supplements should take their vitamins at least 4 hours prior to Welchol. Caution should be exercised when treating patients with a susceptibility to vitamin K or fat-soluble vitamin deficiencies.

Caution should also be exercised when treating patients with gastroparesis, gastrointestinal motility disorders, a history of major gastrointestinal tract surgery, and when treating patients with dysphagia and swallowing disorders.

Welchol interacts with some drugs. Drugs with a known interaction with colesevelam (cyclosporine, glimepiride, glipizide, glyburide, levothyroxine, olmesartan medoxomil, oral contraceptives [ethinyl estradiol, norethindrone], and metformin extended release [ER]) should be administered at least 4 hours prior to Welchol. Drugs that have not been tested for interaction with colesevelam, especially those with a narrow therapeutic index, should also be administered at least 4 hours prior to Welchol. Alternatively, the physician should monitor drug levels of the co-administered drug.

To avoid esophageal distress, Welchol for Oral Suspension should not be taken in its dry form.

Due to tablet size, Welchol for Oral Suspension is recommended for, but not limited to, use in the pediatric population as well as in any patient who has difficulty swallowing tablets.

Phenylketonurics: Welchol for Oral Suspension contains 27 mg phenylalanine per 3.75 gram dose.

Adverse Reactions

In clinical trials, the adverse reactions observed in ≥2% of patients, and more commonly with Welchol than placebo, regardless of investigator assessment of causality seen in:

  • Adult patients with Primary Hyperlipidemia were: constipation, dyspepsia, nausea, accidental injury, asthenia, pharyngitis, flu syndrome, rhinitis, and myalgia
  • Pediatric patients with heFH primary hyperlipidemia were: nasopharyngitis, headache, fatigue, creatine phosphokinase increase, rhinitis, and vomiting
  • Adult patients with Type 2 Diabetes were: constipation, hypoglycemia, dyspepsia, nausea, hypertension, and back pain

Post-marketing experience: Due to the voluntary nature of these reports it is not possible to reliably estimate frequency or establish a causal relationship:

  • Increased seizure activity or decreased phenytoin levels have been reported in patients receiving phenytoin concomitantly with Welchol
  • Reduced International Normalized Ratio (INR) has been reported in patients receiving warfarin concomitantly with Welchol
  • Elevated thyroid-stimulating hormone (TSH) has been reported in patients receiving thyroid hormone replacement therapy
  • Dysphagia has been reported with both tablet and oral suspension formulations

Welchol is Pregnancy Category B.

Please click here for Full Prescribing Information about Welchol.

Savings Card Offer

Savings Card Offer: Eligibility Criteria and Terms & Conditions

To the Patient: You must present this card to pharmacist along with your WELCHOL® (colesevelam HCl) prescription to participate in the program. For patients with commercial insurance, savings per prescription of WELCHOL will apply after the following out-of-pocket expenses are met: $10 per prescription for a 30-day supply of WELCHOL or $0 per prescription for a 90-day supply of WELCHOL. Offer may not be combined with any other program offer or discount for WELCHOL. Savings for WELCHOL are subject to a maximum benefit of $150 per 30-day prescription or $450 per 90-day prescription. If you have questions regarding your eligibility or benefits, or wish to discontinue participation, call (866) 566-4606 (8 AM – 8 PM ET, M-F). When you use this card, you are certifying that you understand the program rules, regulations, and terms and conditions. You are not eligible if you are enrolled in any state or federal health care program, including, but not limited to, Medicare Part D or Medicaid, VA, DOD, or TRICARE/CHAMPUS; or where taxed, restricted, or prohibited by law; or if you do not otherwise comply with the terms of this card. Further, you agree to discontinue using the card if you enroll in any state or federal health care program during the program period. Offer valid in US and Puerto Rico only.

To the Pharmacist: When you use this card, you are certifying that the patient is not enrolled in any federal, state, or other governmental programs for this prescription.

  • Submit transaction to McKesson Corporation, using BIN #610524.
  • If primary coverage exists, input card information as secondary coverage and transmit using the COB segment of NCPDP transaction. Applicable discounts will be displayed in the transaction response.
  • Acceptance of this card and your submission of claims for the WELCHOL ADDvantage Program are subject to LoyaltyScript® program Terms and Conditions posted at
  • Patient not eligible if enrolled in any state or federal health care program, including, but not limited to, Medicare Part D or Medicaid, VA, DOD, or TRICARE/CHAMPUS, or where taxed, restricted or prohibited by law. Offer valid in US and Puerto Rico only.
  • LoyaltyScript® is not an insurance card. For questions regarding setup, claim transmissions, patient eligibility, or other issues, call LoyaltyScript® for the WELCHOL Savings Plan at (866) 566-4606 (8 AM – 8 PM ET, M-F).

Daiichi Sankyo, Inc., reserves the right to rescind, revoke, or amend this program, at any time, without notice.

Trademarks not owned by Daiichi Sankyo, Inc., are property of their respective owners.

Move Up Button

Home Footer Reference

Site global Footer